The activity of anti-PD1 agents has instead been very limited in DLBCL [32]; among 121 patients with r/r DLBCL ineligible for auto-HCT (n = 34) or who relapsed/progressed after auto-HCT (n = 87) treated with nivolumab, 10 patients achieved a response (8.2%), complete in 3, with a median PFS of 1.9 months [33]. This evidence concerns the gene PDCD1 and diffuse large B-cell lymphoma.